CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Apr 11, 2005
This company, along with the other drug stocks, has had a very big problem. Fell below its 200 day moving average. There is no base.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$26.46

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 28, 2005
(A Top Pick Jan24/05. Up 8%.) Still likes.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.23

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Mar 21, 2005
Pharmaceuticals have pretty good cash flows, but their stocks are going nowhere. Cheap on a relative basis to where they've been. Have one big overhang as a group, i.e., there are a lot of patent expiries that are going to happen in 2006. May not be a bad time to start picking them up.
Photo of Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$25.71

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2005
A good long term hold. Historically cheap.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$26.29

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 25, 2005
Likes the pharmaceutical industry. The market is not thinking about the tremendous amount of cash they throw off and that they are cheap. Made the right move by not taking Celebrex off the market. Good pipeline.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.86

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2005
In their top 10. Great valuation.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 18, 2005
FDA has given the OK on the controversial drugs. Pfizer is a very strong company and has the best pipeline of all the large drug companies. Continues to generate billions of $'s of free cash flow. YOu won't get rich, but you'll make some money.
Photo of Andrew McCreathAndrew McCreath
Owned
Unlock Rating
$26.80

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 09, 2005
Over a 3/5 year period, it's probably OK, but it's trending down and there's no reason to get in the way of that until it changes direction. There is pricing pressure in the drug industry, product liability questions, cross border shopping , etc.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.05

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Likes this one a lot. Trading at 11 X earnings and a 3% dividend yield and waiting to see if Cellebrex gets FDA OK. Downside is pretty limited.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Big headline risk and he loves stock with headline risks. Trading at a 50% discount to what it's really worth.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 07, 2005
There is no technical sign that the ugliness has changed yet. No real strong support for the stock here. However, long term pharma sector is an interesting play.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 03, 2005
All the drug stocks in the US have dropped, but this had the best performance of all of them. Their Cellebrex has not been pulled and this has created some negatives. 3.2% yield and if it turns out the FDA finds no problem with the drug, it will be a major factor. Selling for 11 X earnings. Good price.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$23.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 31, 2005
FDA is becoming a lot more stricter with their criteria. Drug companies pipelines are a little bit thin now. A lot of competition. Valuations are cheaper than they've ever been. May not see any gains for a while.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$24.16

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 24, 2005
The industry as a whole has been in a difficult time. A lot of the stuff has been discounted in the stock. Trading at a very cheap multiple. Lots of cash and a high dividend yield. Good long term hold 4/5 years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.26

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 21, 2005
A tough BUY, but given the valuation, if you have a 3/5 year time horizon the positives outweigh the negatives.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$24.48

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 676 to 690 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BUG 4.27$44.31
GS -40.73$988.45
NFLX 2.92$80.32
DAL -0.11$79.8
DML.TO -0.16$4.03
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CP.TO 1.15$124.99
VRT -19.67$237.39
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79

Most Recent Experts

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like